BRCA2 and familial pancreatic carcinoma: This includes pancreatic atrophy in 3 BRCA1 (21.4%) patients and 1 BRCA2 (16.7%) patient, mass lesions later identified as pancreatic cancer in 1 BRCA1 (7.1%) patient and 1 BRCA2 (16.7%) patient, pancreatic cysts in 2 BRCA1 (14.3%) patients, and pancreatic ductal dilation in 1 BRCA1 (7.1%) patient and 1 BRCA2 (16.7%) patient (Table 2, Figure 3).